Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessina C McGregor

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 28, 2014
Optimizing research methods used for the evaluation of antimicrobial stewardship programsJessina C McGregor, Jon P Furuno
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2006
What infection control interventions should be undertaken to control multidrug-resistant gram-negative bacteria?Anthony D Harris, Jessina C McGregor, Jon P Furuno
Therapeutics and Clinical Risk Management|February 12, 2009
Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritisJessina C McGregor, George P Allen, David T Bearden
BMC Pharmacology & Toxicology|April 17, 2021
Opportunities for successful de-escalation of proton pump inhibitors at a federally qualified health centerJoelle Ayoub, Jessina C McGregor, Rebecca M Castner, et al.
CNS Drugs|June 27, 2012
Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover studyDaniel M Hartung, Luke Middleton, Leanne Svoboda, et al.
American Journal of Infection Control|April 25, 2008
Economics of infection control surveillance technology: cost-effective or just cost?Jon P Furuno, Marin L Schweizer, Jessina C McGregor, et al.
Neurology. Clinical Practice|September 26, 2022
Association Between Pharmacy Benefit Restrictions and Disease-Modifying Therapy Use in the Medicare Part D ProgramDaniel M Hartung, Kirbee A Johnston, Jessina C McGregor, et al.
International Journal of MS Care|April 25, 2022
Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare PopulationDaniel M Hartung, Kirbee A Johnston, Jessina C McGregor, et al.
Infection Control and Hospital Epidemiology|October 20, 2020
Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literatureLauren M Fontana, Angela Holly Villamagna, Monica K Sikka, et al.
Multiple Sclerosis and Related Disorders|October 8, 2020
The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosisDaniel M Hartung, Kirbee A Johnston, Jessina C McGregor, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 28, 2014
Optimizing research methods used for the evaluation of antimicrobial stewardship programsJessina C McGregor, Jon P Furuno
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2006
What infection control interventions should be undertaken to control multidrug-resistant gram-negative bacteria?Anthony D Harris, Jessina C McGregor, Jon P Furuno
Therapeutics and Clinical Risk Management|February 12, 2009
Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritisJessina C McGregor, George P Allen, David T Bearden
BMC Pharmacology & Toxicology|April 17, 2021
Opportunities for successful de-escalation of proton pump inhibitors at a federally qualified health centerJoelle Ayoub, Jessina C McGregor, Rebecca M Castner, et al.
CNS Drugs|June 27, 2012
Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover studyDaniel M Hartung, Luke Middleton, Leanne Svoboda, et al.
American Journal of Infection Control|April 25, 2008
Economics of infection control surveillance technology: cost-effective or just cost?Jon P Furuno, Marin L Schweizer, Jessina C McGregor, et al.
Neurology. Clinical Practice|September 26, 2022
Association Between Pharmacy Benefit Restrictions and Disease-Modifying Therapy Use in the Medicare Part D ProgramDaniel M Hartung, Kirbee A Johnston, Jessina C McGregor, et al.
International Journal of MS Care|April 25, 2022
Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare PopulationDaniel M Hartung, Kirbee A Johnston, Jessina C McGregor, et al.
Infection Control and Hospital Epidemiology|October 20, 2020
Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literatureLauren M Fontana, Angela Holly Villamagna, Monica K Sikka, et al.
Multiple Sclerosis and Related Disorders|October 8, 2020
The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosisDaniel M Hartung, Kirbee A Johnston, Jessina C McGregor, et al.
Pageof 9